Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors
D. Aziz, N. Portman, K. Fernandez, C. Lee, S. Alexandrou, A. Llop-Guevara, A. Yong, A. Wilkinson, C. M. Sergio, D. Ferraro, D. Etemadmoghadam, D. Bowtell, k. Investigators, V. Serra, P. Waring, , C. E. Caldon
The paper identifies cyclin E1 stabilization in BRCA1-mutated breast cancers and shows synergy between CDK2 and PARP inhibitors in treating these cancers.
bioRxiv · Jan 29, 2020Cancer Biology